Plus Therapeutics Announces Dr. Gregory Stein as Head of Clinical Development
AUSTIN, Texas, April 01, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: ) (the “Company”), today announced that Dr. Gregory Stein has joined the Company as Senior Vice President of Clinical Development.
Dr. Stein is a highly regarded founder and executive of several healthcare and biotechnology companies. Most recently he co-founded and served as Chief Executive Officer at Curtana Pharmaceuticals, which develops drugs for the treatment of glioblastoma and other brain cancers. Curtana was awarded funding from the Cancer Prevention and Research Institute of Texas.
Prior to Curtana, Dr. Stein was also a founder and served as the Vice President, Operations and Medical Affairs at Sova Pharmaceuticals, Inc., a venture-backed company that developed therapies for sleep-related breathing disorders and neuropathic pain. In addition, Dr. Stein has held senior positions at Genoptix, Opus Pharmaceuticals and Uzima Bioscience.
Dr. Stein was formerly a board-certified Emergency Medicine Physician and previously practiced in Chicago, serving as the Assistant Medical Director of the department and Associate Emergency Medical Services Director for the regional EMS system.
Dr. Stein is a graduate of the accelerated program at the Ohio State University School of Medicine and completed his residency at the University of Illinois Affiliated Hospitals in Chicago. In addition, Dr. Stein has an MBA from The Rady School of Management at UC San Diego.
"Dr. Gregory Stein is an accomplished physician with a successful track record in drug development while in industry,” said Dr. Marc Hedrick, President and CEO of Plus Therapeutics. “Greg’s background, and in particular deep knowledge in neuro-oncology, make him an ideal addition to our world class team.”
About Plus Therapeutics, Inc.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development, and delivery of complex and innovative treatments for patients battling cancer and rare diseases.
Our proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology. Liposomal encapsulation has been extensively explored and undergone significant technical and commercial advances since it was first developed. Our platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate and similar expressions or future conditional verbs such as will, should, would, could or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements about: the Company’s potential to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers; the Company’s potential to develop a market leading position; and the potential for, and timing of, the Company’s submission of a Phase 2 clinical trial protocol in Small Cell Lung Cancer patients with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy. The forward-looking statements included in this press release are subject to a number of additional material risks and uncertainties, including but not limited to: the risk that the U.S. FDA does not accept the Company’s submission of a Phase 2 clinical trial protocol in Small Cell Lung Cancer patients with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy; the risk that the Company is not able to successfully develop product candidates that can leverage the U.S. FDA’s accelerated regulatory pathways; and the risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Plus Therapeutics, Inc.
Andrew Sims
CFO/VP, Investor Relations
Phone: +1.619.333.4150
Email:
Website:
